Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) traded up 23.9% during mid-day trading on Monday . The stock traded as high as $10.76 and last traded at $10.53. 82,298,499 shares were traded during trading, an increase of 344% from the average session volume of 18,530,172 shares. The stock had previously closed at $8.50.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the stock. Needham & Company LLC reiterated a "buy" rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp cut their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th.
Read Our Latest Analysis on RXRX
Recursion Pharmaceuticals Stock Performance
The business's fifty day moving average price is $7.52 and its two-hundred day moving average price is $7.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market capitalization of $3.63 billion, a P/E ratio of -6.07 and a beta of 0.86.
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new position in Recursion Pharmaceuticals in the 4th quarter worth about $54,000. CSS LLC IL bought a new position in Recursion Pharmaceuticals in the 4th quarter worth about $366,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Recursion Pharmaceuticals by 5.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,259,178 shares of the company's stock worth $15,272,000 after acquiring an additional 118,428 shares in the last quarter. Vident Advisory LLC bought a new position in Recursion Pharmaceuticals in the 4th quarter worth about $80,000. Finally, Squarepoint Ops LLC bought a new position in Recursion Pharmaceuticals in the 4th quarter worth about $544,000. 89.06% of the stock is currently owned by institutional investors.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
